Download the GLP-1 Obesity Deal Trends Report for analysis on dealmaking, investment, and innovation in the obesity therapeutics market. Essential for pharma, biotech, and financial professionals in business development, licensing, and portfolio strategy.| Evaluate
Trusted commercial intelligence, consensus forecasts, news and analysis for pharma, biotech and medtech industry - Explore Evaluate| Evaluate
Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Key announcements and data from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with accompanying analyses.| Evaluate
Biotech industry insights. Discover the key factors for biotech commercialization success, including strategic planning, hiring, and funding.| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
Insmed CEO Will Lewis talked to Evaluate about the biotech’s orphan drug strategy, why it is still committed to rare diseases, and how orphan drug benefits might be better targeted.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
